A2A Pharmaceuticals, Inc., 10% Owner at Biomea Fusion, Inc. (BMEA), bought 30,684 shares at $13.87 ($426K) on 2022-08-16, disclosed to the SEC on 2022-08-19.
Scheduled purchase ($426k) by 10% Owner.
Negative factors outweigh the positive ones.
| Filing → |
| BMEA | SELL | 2023-05-10 | $8.6M | — | Filing → |
| BMEA | SELL | 2023-04-26 | $5.8M | — | Filing → |
| BMEA | SELL | 2023-04-06 | $6.3M | — | Filing → |